Diagnos A.I. retinal screening technology expands into international markets
Retrieved on:
Thursday, August 5, 2021
Efficiency, Industry, ADK, Optometry, Multimedia, Eye, Toronto Stock Exchange, Severe cognitive impairment, Hospital, Algorithm, Chum, Artificial intelligence, Ai, Retina, Jody Vance, Capillary, Federal Commission for the Protection against Sanitary Risk, Diabetes, EC, Food and Drug Administration, Clinic, FRA, Solution, Anomaly, Population, Technology, Vein, Levon Larents, Cara, Medicine, Stroke, Partnership, Artery, Health Canada, Aneurysm, BCI, Patient safety, Adoption, Atherosclerosis, Blockade IMARC, Patient, Bleeding, AV, Risk, Adult, Iris, Disease, Drug, Medical device, Medical imaging, Telescopic sight, Cryptocurrency, Pharmaceutical industry
CARA's artificial intelligence-based image enhancement algorithms provide sharper, clearer, retinal images that can then be analyzed for anomalies.
Key Points:
- CARA's artificial intelligence-based image enhancement algorithms provide sharper, clearer, retinal images that can then be analyzed for anomalies.
- "IRIS continues to be at the forefront of implementing technology driven solutions for clinical optometry and optical retail," stated said Eric Babin, President of IRIS.
- "Artificial intelligence will raise our standard when it comes to quality of care and we are eager to collaborate with Diagnos."
- Diagnos' technology can inform a patient that she is at risk for a heart attack or stroke.